Startup PhysIQ Successfully Overcomes Leading Hurdle on the Path to Commercialization

InsightAcceleratorLabsLogoThe focused technology development efforts of Insight Accelerator Labs member PhysIQ were recently rewarded with FDA 510(k) clearance for the company’s personalized physiology analytics system. The startup’s technology, which has been categorized as a Class II device for patient monitoring by the FDA, analyzes a user’s physiological data – including heart rate, respiration rate, oximetry, and blood pressure – to create a personalized baseline for each user and identify exacerbations earlier.

“Without question, FDA clearance is one of the most significant hurdles to overcome, and we’re excited to see PhysIQ reach this major development milestone on their clear path to commercialization,” says Steve McPhilliamy, partner at Insight Product Development, and executive director of Insight Accelerator Labs.

PhysIQ is actively building its platform for any organization that is aggregating biometrics from different devices. The company has already partnered with Samsung on SAMI, a platform Samsung created to collect data from various devices, and with the Scripps Translational Science Institute (STSI) to create a program that uses health sensors to improve the health outcomes of Ebola patients. In 2014 the company raised $4.6 million in a round led by LionBird.

To learn more about Insight Accelerator Labs and its process for helping startups advance their technologies toward commercialization, contact Steve McPhilliamy at